We’re learning more about the potential economic impact of building a Sphere entertainment venue in Maryland. A recent third-party study conducted by accounting firm Ernst & Young predicts a Sphere at ...

Sphere-9 demonstrated 73.8% freedom from AFib vs. only 65.8% observed in the control arm. AFib is one of the most common and undertreated heart rhythm disorders, affecting more than 60 million people ...

GlaxoSmithKline (GSK) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) has completed a significant clinical study titled ‘Study in Pediatrics With HypEREosinophilic Syndrome ...

Interim results highlight six-month outcomes for patients treated with the Sphere-9 catheter for sustained monomorphic ventricular tachycardia (VT) Breakthrough device designation granted for use of ...